Hide metadata

dc.contributor.authorWestvik, Åsbjørn S
dc.contributor.authorWeedon-Fekjær, Harald
dc.contributor.authorMæhlen, Jan
dc.contributor.authorLiestøl, Knut
dc.date.accessioned2018-02-27T05:59:12Z
dc.date.available2018-02-27T05:59:12Z
dc.date.issued2018
dc.identifier.citationBMC Cancer. 2018 Feb 20;18(1):209
dc.identifier.urihttp://hdl.handle.net/10852/60400
dc.description.abstractBackground Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels after introducing mammography screening can be reproduced assuming only progressive tumors. Methods Breast cancer incidence data 1990–2009 obtained from the initially screened Norwegian counties (Akershus, Oslo, Rogaland and Hordaland) was included, covering the time-period before, during and after the introduction of mammography screening. From 1996 women aged 50–69 were invited for biennial public screening. Using estimates of tumor growth and screening sensitivity based on pre-screening and prevalence screening data (1990–1998), we simulated incidence levels during the following period (1999–2009). Results The simulated incidence levels during the period with repeated screenings were markedly below the observed levels. The results were robust to changes in model parameters. Adjusting for hormone replacement therapy use, we obtained levels closer to the observed levels. However, there was still a marked gap, and only by assuming some tumors that undergo regressive changes or enter a markedly less detectable state, was our model able to reproduce the observed incidence levels. Conclusions Models with strictly progressive tumors are only able to partly explain the changes in incidence levels observed after screening introduction in the initially screened Norwegian counties. More complex explanations than a time shift in detection of future clinical cancers seem to be needed to reproduce the incidence trends, questioning the basis for many over-diagnosis calculations. As data are not randomized, similar studies in other populations are wanted to exclude effect of unknown confounders.
dc.language.isoeng
dc.rightsThe Author(s).
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleEvaluating different breast tumor progression models using screening data
dc.typeJournal article
dc.date.updated2018-02-27T05:59:13Z
dc.creator.authorWestvik, Åsbjørn S
dc.creator.authorWeedon-Fekjær, Harald
dc.creator.authorMæhlen, Jan
dc.creator.authorLiestøl, Knut
dc.identifier.doihttp://dx.doi.org/10.1186/s12885-018-4130-2
dc.identifier.urnURN:NBN:no-63052
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/60400/1/12885_2018_Article_4130.pdf
dc.type.versionPublishedVersion
cristin.articleid209


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International